Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Informative Exhibition for Deprescribing Benzodiazepines

NCT06467019 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2024-06-13
Last updated
2026-10-27

Condition(s) studied

Benzodiazepine-Related Disorders

Investigational drug(s) / intervention(s)

Informative Session

Informative Session: The intervention consists of implementing an interactive exhibition on the risks of chronic benzodiazepine treatment in the waiting room of a primary care center. Additionally, the health professionals at the center will receive a single informative session on the same topic.

Study summary

The goal of this trial is to determine if an interactive and informative exhibition in the waiting room of a Primary Care Clinic can reduce the use of benzodiazepines in adults. The main question it aims to answer is:

• Does an interactive and informative exhibition reduce the number of participants using benzodiazepines? Researchers will compare benzodiazepine consumption before and after the interactive and informative exhibition implementation at study center.

Participants will receive an informative and interactive exhibition on the risks of chronic benzodiazepine use. A single informative session on the same topic will be conducted for health professionals.

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Men and women between 18 and 99 years of age. * Attended at the Baix-a-Mar Primary Care Center during the study period. Exclusion Criteria: * Severe mental health disease * Displaced patients or those who do not have an assigned doctor at the center. * Participation in another study involving an experimental intervention during the period of the present study that affects benzodiazepine prescription.

Primary outcome measure(s)

  • Chronic treatment with benzodiazepines — 1 year
    Percentage of patients treated chronically with benzodiazepines, based on electronic prescription data.

Trial sites (1)

FacilityCityRegionStatus
Centro de Salud Vilanova i la Geltrú 3 Baix A Mar Vilanova i la Geltrú Barcelona Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06467019 on ClinicalTrials.gov ↗ ← All trials in Spain